In MM, we have shown that the antiproliferative effects of EZH2 inhibition are concurrent with downregulation of known MM oncogenes, such as IRF-4, XBP-1, PRDM1, and MYC, which is potentially mediated by the induced expression of miR-125a-3p and miR-320c [172]. Here, PRDM1 is linked to Miyoshi myopathy.